Endpoints News· @endpts · X·· 2 天前精选AI 评分72
AI 导读
Kodiak的眼科药物在湿性AMD的III期试验中与Eylea疗效相当，且所需注射次数更少，消息公布后公司股价上涨逾一倍。公司计划于第四季度向FDA提交上市申请。
推荐理由
该III期数据给出与Eylea头对头比较的疗效与注射频次结果，可观察湿性AMD竞品的差异化方向。
正文
Kodiak's stock more than doubled after its eye drug matched Eylea in wet AMD with fewer injections. An FDA filing is coming in the fourth quarter. https://endpoints.news/kodiaks-stock-soars-as-it-clinches-crucial-phase-3-win-for-eylea-competitor/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=
来源：Endpoints News · x.com